Individual Stock News:
1. Zhou Liufu (06168.HK) responded to abnormal stock price fluctuations: The company is unaware of the cause; business operations are normal and stable.
2. Shijiazhuang Pharmaceutical Group (01093.HK): Daratumumab injection received clinical trial approval in China.
3. Hansit Aite-B (03378.HK): Approved to conduct clinical trials of HX111 for injection in China.
4. Sunac China (01918.HK): Approximately US$9.6 billion of the company's existing offshore debt has been fully discharged and forgiven.
5. Tencent Holdings (00700.HK): A board meeting will be held on March 18 to approve full-year results and announcements.
6. Runge Interactive (02422.HK): Plans to place up to 160 million shares at a discount of approximately 19.44%, raising net proceeds of approximately HK$68.6 million.
7. Xipuni (02583.HK) issued a profit warning: The Group expects to record higher net profit for the year ended December 31, 2025.
8. AEON CREDIT (00900.HK) released its Q3 results: Profit for the period was HK$353 million, an increase of 28.11% year-on-year.
9. Shanghai Fudan (01385.HK): Guosheng Investment plans to acquire a 12.99% stake in the company for approximately RMB 5.144 billion, becoming its largest shareholder.
10. Caixing Toys (00869.HK): The "Teenage Mutant Ninja Turtles" franchise agreement will not be renewed from 2027 onwards. The Board will assess the impact of the non-renewal of the franchise agreement on the Group's financial performance.
11. Grand Pharmaceutical (00512.HK): Reached a product cooperation agreement with Youer Pharmaceutical, obtaining exclusive commercialization rights for the world's first nasal spray adrenaline product, Youminsu, in the cooperative channels in mainland China, etc.
